Clinical Pharmacology & Therapeutics: Current Understanding Of Rheumatoid Arthritis Therapy

“Progress in understanding the cellular and molecular mechanisms of rheumatoid arthritis (RA), together with the availability of new therapies, has changed the way we think about RA. The paradigm shift in RA therapy has been from controlling symptoms to controlling the disease process with the abrogation of inflammation. Challenges that are still unresolved include the issues in disease prevention, treatment specificity to restore tolerance, approaches to facilitate tissue repair, and treatment optimization to fit the individual patient’s disease phenotype and comorbidity context. This review summarizes the pathogenesis-related rationales for the current therapeutic strategies in RA and for emerging therapies and potential approaches to restoring immune tolerance in RA.”

Read More: http://www.nature.com/clpt/journal/v91/n4/full/clpt2011325a.html

1 Comment

The Press Association: Rheumatoid Arthritis Breakthrough

A drug that “blindfolds” white blood cells could provide a new way of treating rheumatoid arthritis, new research has shown.

The drug stops the destructive cells migrating to the joints, where they cause the typical damage associated with the disease.

Rheumatoid arthritis is an auto-immune disease in which elements of the immune system attack the body. White blood cells called T-cells are key players in the process.

Study leader Dr Graeme O’Boyle, from the University of Newcastle, said; “Imagine that the damaged joint is covered in flags which are signalling to the white blood cells. Traditional treatments have involved pulling down the flags one by one but what we have done is use an agent which in effect ‘blindfolds’ the white blood cells.

“Therefore, they don’t know which way to travel and so won’t add to the damage.”
The study, funded by the charity Arthritis Research UK, is published in the journal Proceedings of the National Academy of Sciences.

Read More: http://www.google.com/hostednews/ukpress/article/ALeqM5hu…

4 Comments

New York Times: Supply of Methotrexate May Run Out Within Weeks

“This is dire,” said Valerie Jensen, associate director of the Food and Drug Administration’s drug shortages program. “Supplies are just not meeting demand.”

The drug is methotrexate, and the cancer it treats is known as acute lymphoblastic leukemia, or A.L.L., which most often strikes children ages 2 to 5. It is an unusually virulent cancer of white blood cells that are overproduced in bone marrow and invade other parts of the body.

The cancer commonly spreads to the lining of the spine and brain, and oncologists prevent this by injecting large quantities of preservative-free methotrexate directly into the spinal fluid. The preservative can cause paralysis when injected into the spinal column, so cannot be used for this disease. Methotrexate is also used to treat rheumatoid arthritis.

Read More: http://www.nytimes.com/2012/02/11/health/policy/supply-of-methotrexate-a-cancer-drug-may-run-out-soon.html?_r=1

7 Comments

Women’s Health Magazine: When Your Body Attacks

When Venus Williams bowed out of the U.S. Open last fall due to Sjogren’s syndrome, you may have thought, What? But her problem is more common than many think. Sjogren’s belongs to a group of some 80 autoimmune diseases in which the immune system goes haywire and attacks healthy tissue and organs.

Most such illnesses share a few traits: They are on the rise, run in families, are most prevalent in women, and are notoriously difficult to figure out. Patients often see four or more doctors over five years before being correctly diagnosed or finding proper treatment. The key is to identify the disease before it does any lasting damage. Here’s how a handful of women and their doctors unraveled the mysteries of five common conditions.

Read more: http://www.womenshealthmag.com/health/immune-system-fix

2 Comments

This is a post with post format of type Link

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus.

0 Comments